Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis
Is ALNY a good investment?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 72.0/100 as of August 24, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: PEG ratio of 0.34 vs. industry average 6.20 (94.5% discount) — ALNY is the most attractively valued high-growth compounder in biotech; analyst consensus target $373.05 implies 57.9% upside from $236.22; 5-year EPS CAGR of 71.9% vs. industry 18.9% (279.9% premium) confirms long-duration compounding thesis with real commercial momentum (revenue +66.9% YoY). Main concern: Active multi-firm securities fraud investigations (Bragar Eagel & Squire, Kessler Topaz Meltzer & Check headlines confirmed in current news cycle) triggered by Q2 2026 EPS miss ($1.84 vs. $2.05 consensus, -10%) and guidance cut causing ~28% single-day decline — news sentiment 8.0/100 with 14/16 articles negative; if investigations reveal undisclosed information about Amvuttra demand normalization, legal liability and reputational damage could be severe; this overhang suppresses near-term multiple expansion.
Investment Summary
Alnylam Pharmaceuticals (ALNY) at $236.22 presents one of the most compelling growth-adjusted valuations in biotech — PEG ratio of 0.34 vs. industry average of 6.20 (94.5% discount), 5-year EPS CAGR of 71.9% vs. industry 18.9%, gross margin of 79.7% vs. industry 32.95%, and analyst consensus target of $373.05 implying 57.9% upside. However, the near-term narrative is dominated by an active, multi-firm securities fraud investigation (Bragar Eagel & Squire, Kessler Topaz Meltzer & Check, Glancy Prongay Wolke & Rotter) triggered by a Q2 2026 EPS miss of $1.84 vs. $2.05 consensus (-10%) and a guidance cut that caused a ~28% single-day decline. News sentiment has deteriorated to 8.0/100 with 14 of 16 articles negative — unchanged from the prior report. No metrics have moved materially since the prior report (stock price flat at $236.22, analyst target flat at $373.05, P/E flat at 39.88, PEG flat at 0.34, revenue growth flat at 66.9%). The exceptional fundamentals remain intact and the legal risk remains a disclosure/governance problem rather than a business destruction event. Rating held at 72.0.
Key Strengths
- PEG ratio of 0.34 vs. industry average 6.20 (94.5% discount) — ALNY is the most attractively valued high-growth compounder in biotech; analyst consensus target $373.05 implies 57.9% upside from $236.22; 5-year EPS CAGR of 71.9% vs. industry 18.9% (279.9% premium) confirms long-duration compounding thesis with real commercial momentum (revenue +66.9% YoY)
- Profitability unmatched in biotech: gross margin 79.7% (141.8% above industry 32.95%), operating margin +17.9% (vs. industry -6,005%), net margin +16.8% (vs. industry -3,353%), ROE 100.7% (vs. industry -72.87%); $3.31B cash + $271.5M positive FCF confirm self-funding commercial-stage status that virtually no biotech peer has achieved
- P/E of 39.88x is 8.6% below industry average of 43.65x despite ALNY delivering 4x the long-term EPS growth rate of the average peer — cheaper on earnings than the average biotech while growing dramatically faster; one bullish analyst initiation in recent coverage corroborates the fundamental undervaluation thesis
Key Concerns
- Active multi-firm securities fraud investigations (Bragar Eagel & Squire, Kessler Topaz Meltzer & Check headlines confirmed in current news cycle) triggered by Q2 2026 EPS miss ($1.84 vs. $2.05 consensus, -10%) and guidance cut causing ~28% single-day decline — news sentiment 8.0/100 with 14/16 articles negative; if investigations reveal undisclosed information about Amvuttra demand normalization, legal liability and reputational damage could be severe; this overhang suppresses near-term multiple expansion
- D/E of 1.98 (84.6% above industry average 1.07) creates amplified downside risk if revenue growth decelerates; analyst consensus target has declined from $391.83 → $379.10 → $375.34 → $373.05 over recent weeks (cumulative -4.8% decline), signaling continued modest downward revisions; stock at $236.22 is above the lower bound of the prior entry zone, reducing margin of safety
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ALNY's fundamentals are elite-tier for biotech. Gross margin of 79.7% (vs. industry 32.95%, a 141.8% premium) reflects the pricing power of its proprietary RNAi platform. Operating margin of 17.9% and net margin of 16.8% confirm genuine profitability in a sector where the industry average operating margin is -6,005% due to pre-revenue peers. ROE of 100.7% (vs. industry -72.87%) is extraordinary, though amplified by D/E of 1.98 (vs. industry average 1.07 — an 84.6% leverage premium). P/E of 39.88x is 8.6% below the industry average of 43.65x despite ALNY being one of the only profitable large-cap biotechs. PEG of 0.34 vs. industry 6.20 is the definitive valuation signal — ALNY is priced at one-third of growth-fair value. Revenue growth of 66.9% YoY on a large commercial base validates forward projections. Next-year EPS growth projected at 47.0%; 5-year EPS CAGR of 71.9%. Cash of $3.31 billion and positive FCF of $271.5 million confirm self-funding status. Financial health score of 50/100 reflects the tension between strong liquidity and elevated leverage. Analyst consensus target of $373.05 vs. current $236.22 = 57.9% implied upside.
News Sentiment
Alnylam Pharmaceuticals is navigating a legal storm that has rattled investors, even as the company's underlying business continues to show remarkable strength. Multiple law firms — including Bragar Eagel & Squire and Kessler Topaz Meltzer & Check — have launched securities fraud investigations into the biotech giant, with headlines like 'Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues' appearing repeatedly in recent weeks. These probes were triggered after Alnylam reported Q2 2026 earnings of $1.84 per share, missing Wall Street's $2.05 consensus by 10%, and cut its forward guidance — a one-two punch that sent the stock plummeting roughly 28% in a single day. The investigations are examining whether the company may have misled investors about the demand trajectory for its flagship drug Amvuttra before the disappointing results came to light. That's the bad news. The good news? At least one analyst is stepping up with a bullish take, with a headline noting 'This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note' — though specific price targets weren't disclosed. For everyday investors, the picture is this: Alnylam is a genuinely profitable, fast-growing biotech with $3.3 billion in cash and revenue growing nearly 67% annually. But until the legal cloud clears, the stock is likely to remain under pressure. Patience — and a discounted entry price — is the smart play here.
Risk Assessment
PRIMARY RISK: Active securities fraud investigations by multiple law firms (Bragar Eagel & Squire, Kessler Topaz Meltzer & Check, Glancy Prongay Wolke & Rotter) remain unresolved. These were triggered by the Q2 2026 EPS miss ($1.84 vs. $2.05 consensus) and guidance cut that caused a ~28% single-day decline. If investigations reveal material undisclosed information about Amvuttra demand normalization or forward guidance integrity, legal liability could be substantial and the stock could retest post-guidance-cut lows. SECONDARY RISK: D/E of 1.98 amplifies downside if revenue growth decelerates — any miss against the 47% next-year EPS growth target could cause significant multiple compression from P/E 39.88x. TERTIARY RISK: Analyst consensus target has declined -4.8% over recent weeks ($391.83 → $373.05), suggesting continued modest downward revisions are possible. MITIGATION: Stop loss at $188 (16.4% below entry midpoint $225) limits downside; $3.31B cash provides liquidity buffer; the legal risk is a disclosure/governance issue, not a business destruction event — the RNAi platform and commercial momentum remain intact. Position size of 2.5% reflects elevated near-term legal and guidance risk.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ALNY a halal stock?
No, Alnylam Pharmaceuticals, Inc. (ALNY) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ALNY?
Alnylam Pharmaceuticals, Inc. (ALNY) has a Plutrex AI rating of 72.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ALNY a good investment?
According to Plutrex AI, ALNY has a Buy rating (72.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ALNY?
US stocks like ALNY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ALNY?
Plutrex AI identifies the main risks for ALNY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.